{"id":"NCT00392379","sponsor":"Mayo Clinic","briefTitle":"Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction","officialTitle":"Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2006-10-26","resultsPosted":"2010-08-30","lastUpdate":"2013-04-24"},"enrollment":270,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Smokeless Tobacco Use"],"interventions":[{"type":"DRUG","name":"Nicotine Lozenges","otherNames":["Commit nicotine lozenge"]},{"type":"DRUG","name":"Placebo lozenge","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"This study will be a randomized, blinded, placebo-controlled two-group clinical trial. The independent variable is treatment assignment (active 4-mg nicotine lozenge vs. matching placebo lozenge), and the dependent variables are all tobacco and ST abstinence at 3 and 6 months. ST users will be randomly assigned to either the 4-mg active nicotine lozenge or matching placebo.","primaryOutcome":{"measure":"Prolonged Smokeless Tobacco Abstinence at 3 Months","timeFrame":"3 months","effectByArm":[{"arm":"Nicotine Lozenge","deltaMin":65,"sd":null},{"arm":"Placebo Nicotine Lozenge","deltaMin":41,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":136},"commonTop":["Sleep disturbance","Headache","Reflux"]}}